Research Article
Distressed Communities Index in Patients Undergoing Transcatheter Aortic Valve Implantation in an Affluent County in New York
| | | Distress index <10 (n = 73) | Distress index 10–20 (n = 81) | Distress index 20–30 (n = 80) | Distress index >30 (n = 52) | value |
| | Discharge prescriptions | | Aspirin | 70 (95.9%) | 71 (89.9%) | 76 (96.2%) | 49 (96.1%) | 0.254 | | Clopidogrel | 44 (60.3%) | 49 (62.0%) | 49 (62.0%) | 35 (68.6%) | 0.806 | | Ticagrelor | 0 (0%) | 2 (2.5%) | 1 (1.3%) | 4 (7.8%) | 0.038 | | Warfarin | 16 (21.9%) | 21 (26.6%) | 14 (17.7%) | 10 (19.6%) | 0.576 | | Apixaban | 6 (8.2%) | 5 (6.3%) | 9 (11.4%) | 1 (2.0%) | 0.239 | | Rivaroxaban | 2 (2.7%) | 1 (1.3%) | 2 (2.5%) | 1 (2.0%) | 0.923 | | Dabigatran | 3 (4.1%) | 1 (1.3%) | 3 (3.8%) | 0 (0%) | 0.370 | | Discharge location | | | | | 0.545 | | Home | 58 (79.5%) | 63 (79.7%) | 69 (87.3%) | 42 (82.4%) | | | Skilled nursing facility | 15 (20.5%) | 16 (20.3%) | 10 (12.7%) | 9 (17.6%) | | | Length of stay (days) | | Admission to discharge | 5.1 ± 5.3 | 5.7 ± 6.6 | 5.7 ± 5.1 | 6.2 ± 6.7 | 0.776 | | TAVR procedure to discharge | 3.1 ± 2.1 | 8.0 ± 41.1 | 3.2 ± 2.6 | 3.3 ± 4.0 | 0.424 | | In-hospital | | Major adverse cardiac events | 4 (5.5%) | 10 (12.3%) | 7 (8.8%) | 3 (5.8%) | 0.402 | | All-cause mortality | 0 (0%) | 2 (2.5%) | 1 (1.3%) | 1 (1.9%) | 0.609 | | Disabling stroke | 2 (2.7%) | 1 (1.2%) | 0 (0%) | 0 (0%) | 0.329 | | New pacemaker | 2 (3.3%) | 8 (10.8%) | 6 (9.0%) | 2 (4.2%) | 0.282 | | 30-day (includes in-hospital outcomes) | | Major adverse cardiac events | 4 (5.5%) | 14 (17.3%) | 10 (12.5%) | 4 (7.7%) | 0.102 | | All-cause mortality | 0 (0%) | 2 (2.5%) | 1 (1.3%) | 2 (3.8%) | 0.397 | | Disabling stroke | 2 (2.8%) | 2 (2.5%) | 1 (1.3%) | 0 (0%) | 0.643 | | New pacemaker | 2 (3.3%) | 11 (15.5%) | 8 (12.1%) | 2 (4.3%) | 0.055 | | All-cause readmission | 11 (15.3%) | 21 (26.9%) | 21 (26.6%) | 10 (20.0%) | 0.267 |
|
|
